132 related articles for article (PubMed ID: 33295558)
1. [Epidemiology, resource use and costs of rheumatoid arthritis in Argentina].
Secco A; Alfie V; Espinola N; Bardach A
Rev Peru Med Exp Salud Publica; 2020 Dec; 37(3):532-540. PubMed ID: 33295558
[TBL] [Abstract][Full Text] [Related]
2. Costs and predictors of costs in rheumatoid arthritis: a prevalence-based study.
Lajas C; Abasolo L; Bellajdel B; Hernández-García C; Carmona L; Vargas E; Lázaro P; Jover JA
Arthritis Rheum; 2003 Feb; 49(1):64-70. PubMed ID: 12579595
[TBL] [Abstract][Full Text] [Related]
3. International variation in resource utilisation and treatment costs for rheumatoid arthritis: a systematic literature review.
Rosery H; Bergemann R; Maxion-Bergemann S
Pharmacoeconomics; 2005; 23(3):243-57. PubMed ID: 15836006
[TBL] [Abstract][Full Text] [Related]
4. Economic burden of varicella in children 1-12 years of age in Argentina, 2009-2014.
Giglio N; Monsanto H; Rampakakis E; Yang HK; Kuter BJ; Wolfson LJ
J Med Econ; 2018 Apr; 21(4):416-424. PubMed ID: 29357715
[TBL] [Abstract][Full Text] [Related]
5. The costs of rheumatoid arthritis.
Allaire SH; Prashker MJ; Meenan RF
Pharmacoeconomics; 1994 Dec; 6(6):513-22. PubMed ID: 10155281
[TBL] [Abstract][Full Text] [Related]
6. Economic Burden of Rheumatoid Arthritis in Italy: Possible Consequences on Anti-Citrullinated Protein Antibody-Positive Patients.
Mennini FS; Marcellusi A; Gitto L; Iannone F
Clin Drug Investig; 2017 Apr; 37(4):375-386. PubMed ID: 28074337
[TBL] [Abstract][Full Text] [Related]
7. Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide in rheumatoid arthritis in Germany: I. Selected DMARDs and patient-related costs.
Schädlich PK; Zeidler H; Zink A; Gromnica-Ihle E; Schneider M; Straub C; Brecht JG; Huppertz E
Pharmacoeconomics; 2005; 23(4):377-93. PubMed ID: 15853437
[TBL] [Abstract][Full Text] [Related]
8. Costs of rheumatoid arthritis in France: a multicenter study of 1109 patients managed by hospital-based rheumatologists.
Guillemin F; Durieux S; Daurès JP; Lafuma A; Saraux A; Sibilia J; Bourgeois P; Sany J
J Rheumatol; 2004 Jul; 31(7):1297-304. PubMed ID: 15229947
[TBL] [Abstract][Full Text] [Related]
9. The cost of care of rheumatoid arthritis and ankylosing spondylitis patients in tertiary care rheumatology units in Turkey.
Malhan S; Pay S; Ataman S; Dalkilic E; Dinc A; Erken E; Ertenli I; Ertugrul E; Gogus F; Hamuryudan V; Inanc M; Karaarslan Y; Karadag O; Karakoc Y; Keskin G; Kisacik B; Kiraz S; Oksel F; Oksuz E; Pirildar T; Sari I; Soy M; Senturk T; Taylan A
Clin Exp Rheumatol; 2012; 30(2):202-7. PubMed ID: 22546069
[TBL] [Abstract][Full Text] [Related]
10. Indirect cost assessment in patients with rheumatoid arthritis (RA): comparison of data from the health economic patient questionnaire HEQ-RA and insurance claims data.
Merkesdal S; Ruof J; Huelsemann JL; Mittendorf T; Handelmann S; Mau W; Zeidler H
Arthritis Rheum; 2005 Apr; 53(2):234-40. PubMed ID: 15818718
[TBL] [Abstract][Full Text] [Related]
11. Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7,527 patients.
Michaud K; Messer J; Choi HK; Wolfe F
Arthritis Rheum; 2003 Oct; 48(10):2750-62. PubMed ID: 14558079
[TBL] [Abstract][Full Text] [Related]
12. Estimation of direct cost of managing rheumatoid arthritis treatment to Pakistani patients using real-world follow-up data.
Naqvi AA; Hassali MA; Naqvi SBS; Kachela B; Khan I
Int J Rheum Dis; 2020 Mar; 23(3):325-333. PubMed ID: 31880102
[TBL] [Abstract][Full Text] [Related]
13. Burden of rheumatoid arthritis from a societal perspective: A prevalence-based study on cost of this illness for patients in China.
Hu H; Luan L; Yang K; Li SC
Int J Rheum Dis; 2018 Aug; 21(8):1572-1580. PubMed ID: 28211251
[TBL] [Abstract][Full Text] [Related]
14. Costs of rheumatoid arthritis in Germany: a micro-costing approach based on healthcare payer's data sources.
Ruof J; Hülsemann JL; Mittendorf T; Handelmann S; von der Schulenburg JM; Zeidler H; Merkesdal S
Ann Rheum Dis; 2003 Jun; 62(6):544-9. PubMed ID: 12759292
[TBL] [Abstract][Full Text] [Related]
15. Economic burden of rheumatoid arthritis: a systematic review of literature in biologic era.
Hsieh PH; Wu O; Geue C; McIntosh E; McInnes IB; Siebert S
Ann Rheum Dis; 2020 Jun; 79(6):771-777. PubMed ID: 32245893
[TBL] [Abstract][Full Text] [Related]
16. Economic burden of schizophrenia: empirical analyses from a survey in Thailand.
Phanthunane P; Whiteford H; Vos T; Bertram M
J Ment Health Policy Econ; 2012 Mar; 15(1):25-32. PubMed ID: 22611090
[TBL] [Abstract][Full Text] [Related]
17. An overview of economic evaluations for drugs used in rheumatoid arthritis : focus on tumour necrosis factor-alpha antagonists.
Bansback NJ; Regier DA; Ara R; Brennan A; Shojania K; Esdaile JM; Anis AH; Marra CA
Drugs; 2005; 65(4):473-96. PubMed ID: 15733011
[TBL] [Abstract][Full Text] [Related]
18. [A multicenter cross-sectional study on the health related quality of life of patients with rheumatoid arthritis using a revised Japanese version of the arthritis impact measurement scales version 2 (AIMS 2), focusing on the medical care costs and their associative factors].
Hashimoto A; Sato H; Nishibayahi Y; Shiino Y; Kutsuna T; Ishihara Y; Hoshi K; Fujimori J; Tsuboi S; Kondo H; Akizuki M; Moroi Y; Yoshida S
Ryumachi; 2002 Feb; 42(1):23-39. PubMed ID: 11925904
[TBL] [Abstract][Full Text] [Related]
19. The economic burden of rheumatoid arthritis in a developing nation: results from a one-year prospective cohort study in Thailand.
Osiri M; Maetzel A; Tugwell P
J Rheumatol; 2007 Jan; 34(1):57-63. PubMed ID: 17183621
[TBL] [Abstract][Full Text] [Related]
20. Prevalence and out-patient medical costs of comorbid conditions in patients with rheumatoid arthritis.
Osiri M; Sattayasomboon Y
Joint Bone Spine; 2013 Dec; 80(6):608-12. PubMed ID: 23827409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
